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ABSTRACT
Vitamin D has pleiotropic effects on multiple tissues, including malignant tumors. 
Vitamin D inhibits breast cancer growth through activation of the vitamin D receptor 
(VDR) and via classical nuclear signaling pathways. Here, we demonstrate that the 
VDR can also function in the absence of its ligand to control behaviour of human 
breast cancer cells both outside and within the bone microenvironment. Stable shRNA 
expression was used to knock down VDR expression in MCF-7 cells, generating two 
VDR knockdown clonal lines. In ligand-free culture, knockdown of VDR in MCF-7 
cells significantly reduced proliferation and increased apoptosis, suggesting that the 
VDR plays a ligand-independent role in cancer cell growth. Implantation of these 
VDR knockdown cells into the mammary fat pad of nude mice resulted in reduced 
tumor growth in vivo compared with controls. In the intra-tibial xenograft model, 
VDR knockdown greatly reduced the ability of the cells to form tumors in the bone 
microenvironment. The in vitro growth of VDR knockdown cells was rescued by the 
expression of a mutant form of VDR which is unable to translocate to the nucleus 
and hence accumulates in the cytoplasm.  Thus, our data indicate that in the absence 
of ligand, the VDR promotes breast cancer growth both in vitro and in vivo and that 
cytoplasmic accumulation of VDR is sufficient to produce this effect in vitro. This new 
mechanism of VDR action in breast cancer cells contrasts the known anti-proliferative 
nuclear actions of the VDR-vitamin D ligand complex.
INTRODUCTION
Breast cancer continues to be the most prevalent and 
frequently diagnosed malignancy in women worldwide 
[1]. In the past two decades, advances in early diagnostic 
and treatment strategies have decreased overall breast 
cancer mortality by more than 30% [2, 3]. However, once 
metastases have developed, the prognosis is poor [4–7].
Epidemiological and pre-clinical studies indicate 
an inverse correlation between serum concentrations of 
vitamin D and the development and progression of breast 
cancer [8–10]. Vitamin D deficiency in patients with 
early stage breast cancer is also associated with a poor 
prognosis [11].
The active metabolite of vitamin D, 
1,25-dihydroxy-vitamin D3 (1,25D3) is a steroid hormone 
with pleiotropic effects on multiple tissues including 
bone, the immune system and cancer cells [12, 13]. The 
effects of vitamin D are mediated through binding of 
1,25D3 to the vitamin D receptor (VDR). Upon ligand 
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binding, the VDR forms a heterodimer complex with the 
retinoic acid receptor (RXR), which facilitates nuclear 
translocation and subsequent binding of the complex to 
specific vitamin D response elements (VDRE) within 
the promoters of target genes [14–17]. Well established 
ligand-mediated nuclear actions of the VDR include 
inhibition of cancer cell proliferation, induction of 
apoptosis, and inhibition of metastasis by regulating cell 
migration and invasion [15, 18–21].
Of note, VDR expression also negatively 
correlate with tumor progression: relatively high VDR 
concentrations are found in non-malignant hyperplastic 
tissue while progression to malignant growth is often 
associated with a reduction or complete loss of VDR 
expression [18, 22, 23]. Consistent with these reports, 
invasive breast cancers have been found to have relatively 
low VDR expression compared to normal mammary 
epithelia [22, 24]. Finally, VDR expression in breast 
cancer tissues may be inversely associated with the 
prognosis and survival of patients with breast cancer [25]. 
Collectively, these data suggest that vitamin D action 
through VDR in breast epithelial cells, which may act to 
prevent a switch toward tumorigenicity.
Previous studies in rodents have demonstrated that 
vitamin D deficiency promotes the growth of human 
breast cancer cells in bone [26, 27]. Using a vitamin 
D deficiency mouse model, these studies have shown 
that the acceleration in cancer cell growth was in part 
due to the effects of vitamin D deficiency on the bone 
microenvironment, as hypovitaminosis D induced a 
significant increase in osteoclast-mediated bone resorption 
due to secondary hyperparathyroidism [26, 28]. To further 
determine the interaction between tumor cells and vitamin 
D, bone resorption was inhibited through treatment 
with osteoprotegrin (OPG) in both vitamin D deficient 
and control mice. Interestingly, tumor burden in OPG-
treated mice remained increased in vitamin D deficient 
mice relative to controls. It is thus likely that under these 
circumstances the absence of vitamin D had a direct effect 
on breast cancer growth [26, 27], which in turn poses the 
question as to whether vitamin D exerts direct inhibitory 
effects on cancer cell growth. 
To determine the molecular mechanism of these 
direct effects, we disrupted vitamin D signaling in cancer 
cells and studied tumor growth in bone. Based on the 
known anti-proliferative function of vitamin D signaling, 
we hypothesized that silencing VDR expression in breast 
cancer cells would promote breast cancer growth. We 
therefore knocked down VDR expression in the human 
breast cancer cell line MCF-7 and followed up with clonal 
selection to generate highly efficient knockdown clones. 
In contrast to our initial hypothesis, we discovered that 
VDR knockdown inhibited cancer cell proliferation in the 
absence of vitamin D, suggesting a novel function of the 
VDR in promoting breast cancer cell growth.
RESULTS
Generation of stable VDR knockdown clones 
Parental MCF-7 cells were transduced with 
either the shVDR or shNT construct, then continuously 
maintained with complete media containing puromycin 
and allowed to grow exponentially before being used for 
single cell clonal selection. Out of 30 NT clones, NT#13 
expressed VDR mRNA and protein levels similar to PA 
(Parental MCF-7) cells (Figure 1A, 1C) and was therefore 
selected for all subsequent experiments. 
Out of 27 VDR-KD clones screened, clones #5, 6 
and 16 exhibited knockdown of both VDR mRNA and 
protein expression between 80–85% compared to PA cells 
and NT clones (Figure 1B, 1C). Clones were retested for 
stability of VDR knockdown after culture in the absence 
of puromycin for 8 weeks. After 8 weeks, out of 3 clones, 
VDR knockdown in clones #5 and #6 remained stable 
both at mRNA and protein levels and were used for further 
experiments (Figure 1D, 1E). The overall level of VDR 
gene knockdown among the different VDR-KD clones is 
~50%, which may be due to variability within puromycin-
resistant populations. The average of VDR mRNA levels 
of all VDR-KD clones was significantly reduced as 
compared to the average of VDR mRNA levels of all VDR 
NT clones (Mean ± SEM: 0.961 ± 0.0575 relative VDR 
mRNA in NT clones versus 0.515 ± 0.0553 relative VDR 
mRNA in VDR-KD clones, p < 0.001).
VDR knockdown abrogates vitamin D signaling 
in MCF-7 cells
Treatment with 10–8M 1,25D3 for 24 hours increased 
VDR mRNA and protein expression by NT cells, while 
the two MCF-7-VDR-KD clones showed only marginal 
responses to ligand exposure (Figure 2A, 2B). CYP24 is a 
direct VDR target gene [23, 29] and treatment with 1,25D3 
induced a robust increase in CYP24 mRNA in NT cells 
(Figure 2C). In contrast, CYP24 mRNA induction was 
attenuated in VDR-KD#5 and VDR-KD#6 knockdown 
clones (Figure 2C), indicating effective disruption of VDR 
signaling in both clones.
VDR knockdown reduces MCF-7 cell growth 
and induces apoptosis in ligand-free culture
To test the effect of 10–8M 1,25D3 on the in vitro 
growth of NT and VDR-KD cells, clonal and non-clonal 
lines was tested over 6 days, cells were cultured in 
charcoal-stripped media that lacks 1,25D3. The growth 
rate of MCF-VDR-KD cells prior to clonal selection, 
when the population was still heterogeneous, was first 
examined. Compared to vehicle, treatment with 1,25D3 
significantly reduced the growth of NT cells but not that 
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of VDR-KD cells, consistent with the disruption of VDR 
signaling. Surprisingly, however, the MCF7-VDR-KD 
non-clonal cells showed ligand-independent growth 
inhibitory and pro-apoptotic effects, when compared 
with MCF7-NT non-clonal cells (Figure 3A, 3B).  These 
results were further confirmed using MCF-7-VDR-clonal 
lines. Similar to the non-clonal cell line, we found that 
in the absence of 1,25D3 the growth of both VDR-KD 
clones was significantly decreased compared to NT cells. 
Remarkably, growth of VDR-KD clones in absence of 
1,25D3 was similar to that of NT cells in the presence 
of 1,25D3 (Figure 3C, 3D). Furthermore, treatment with 
1,25D3 increased apoptosis in NT cells. In the absence of 
ligand, apoptosis in VDR-KD clones was significantly 
increased compared to NT cells.  However, 1,25D3 
treatment of VDR-KD clones did not increase apoptosis 
(Figure 3E). These data indicate that loss of the VDR 
decreases the growth of breast cancer cells and induces 
apoptosis independently of its ligand, 1,25D3.
VDR knockdown in MCF-7 cells reduces 
orthotopic tumor growth in vivo
To determine the effects of VDR knockdown in 
MCF-7 cells on orthotopic cell growth, NT and VDR-KD 
cells (clone #5) were implanted into the mammary fat pad 
of vitamin D-replete nude mice. As shown in Figure 4A, 
VDR knockdown significantly reduced tumor growth 
compared to MCF-7-NT cells. At endpoint (day 50 post 
implantation), tumor weight was 72% lower in tumors 
derived from MCF-7-VDR-KD cells compared to those 
grown from MCF-7-NT cells (Figure 4B).
Figure 1: Stable knockdown of VDR in MCF-7 cells. MCF-7 cells were transduced with a lentivirus expressing either a non-target 
shRNA (NT) or shRNA against VDR (VDR-KD) and single cell clones were selected. (A–B) Level of expression of VDR mRNA was 
measured using quantitative RT-PCR in (A) MCF-7 NT clones and (B) MCF-7 VDR-KD clones and compared to parental MCF-7 cells 
(PA). (C) Level of VDR protein in cell lysates of PA, NT and VDR-KD clones was assessed using Western blotting. (D–E) MCF-7 PA 
cells and NT and VDR-KD clones were grown for 8 weeks in absence of antibiotic and VDR mRNA and protein levels were reassessed to 
ensure stable knockdown.
Results are expressed as the mean ± SEM (n = 3). ***p < 0.001 using one-way ANOVA with Tukey’s post-test.
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VDR knockdown in MCF-7 cells impairs tumor 
formation in bone
To determine whether the bone microenvironment 
affects the growth of VDR-KD cells, NT and VDR-KD 
clones were inoculated into the proximal tibiae of vitamin 
D-replete nude mice. Osteosclerotic tumors derived from 
NT cells became radiographically visible 6 weeks post 
inoculation (p.i.), and continued to develop until study 
completion at 21 weeks p.i. In contrast, no obvious X-ray 
changes were identified in the two VDR-KD groups 
throughout the duration of the experiment (Figure 4C). 
Quantitative histomorphometry demonstrated that in the 
NT-inoculated group, 8 out of 9 mice formed tumors. In 
contrast, only 2 out of 9 mice inoculated with VDR-KD cells 
developed histologically identifiable tumors, while in the 
remaining 7 mice no tumor was present (Figure 4D). Tumor 
area was 4.7-fold lower in tibiae inoculated with VDR-KD#5 
compared to NT cells, and similar differences were observed 
with VDR-KD#6 cells (Figure 4D). Trabecular bone volume 
(sclerotic lesion area assessed histomorphometrically) was 
increased in all groups compared to vehicle-inoculated 
tibiae. However, compared to NT controls, the amount of 
trabecular bone volume was significantly lower in tibiae 
inoculated with VDR-KD cells (Figure 4E).
MicroCT analysis revealed that trabecular bone 
volume of tibiae inoculated with NT cells was increased 
by 44-fold compared to vehicle-injected bones. In contrast, 
trabecular bone volume in tibiae inoculated with VDR-
KD#5 and VDR-KD#6 cells increased by only 8 and 18-
fold, respectively, compared to vehicle-injected controls, 
again significantly less than bones inoculated with NT 
cells (Figure 5A, 5B). Trabecular number (Tb.N) in the 
tibiae inoculated with NT was significantly higher than 
in contralateral tibiae as well as the VDR-KD inoculated 
tibiae (Figure 5C).  Similarly, trabecular separation (Tb.Sp) 
in VDR-KD containing bones was 2-fold higher than in 
NT bearing bones (Figure 5D). 
Figure 2: VDR knockdown abrogates vitamin D signaling in MCF-7 cells. (A) In response treatment with 1,25D3 for 24 hours, 
VDR mRNA was increased by 2-fold in NT cells as compared to vehicle treated cells. In contrast, VDR-KD clones showed marginal 
response to the 1,25D3 treatment. (B) After 48-hour treatment with 1,25D3, VDR protein levels were significantly increased in NT treated 
cells. The VDR-KD clones show marginally increased VDR protein levels following treatment. (C) After 24-hour treatment of NT cells, a 
significant induction of CYP24 mRNA was observed compared to vehicle treated cells. In contrast, CYP24 mRNA induction was attenuated 
in VDR-KD clones with 1,25D3 treatment.
Results are expressed as the mean ± SEM (n = 3). ***p < 0.001 NT(-D3) compared to NT (+D3) using one-way ANOVA with Tukey’s post test.
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Trabecular number in the tibiae inoculated with 
NT cells was significantly higher (+456%) compared to 
vehicle control. Tibiae injected with VDR knockdown 
cells showed an increase in trabecular number of up 
to 141% compared to vehicle (Figure 5C). Similarly, 
trabecular separation was decreased by 72% in tibiae with 
NT cells, compared to vehicle inoculated tibiae. Trabecular 
separation in VDR-KD inoculated tibia was reduced up to 
13% compared to vehicle-inoculated tibiae (Figure 5D). 
Collectively, these data indicate that VDR 
knockdown negatively affects the capability of MCF-7 
cancer cells to form tumors and induce osteosclerosis in 
bone following direct intra-tibial inoculation in mice.
Stably expressed mutant VDR (mutVDR) 
accumulates in the cytoplasm
As shown above, knockdown of the VDR in MCF-
7 breast cancer cells reduced growth in ligand-free 
conditions, suggesting that the VDR functions 
independently of 1,25D3 binding to promote cell growth 
in vitro. To further elucidate the function of the VDR 
in breast cancer cells and the underlying molecular 
events. Therefore, we next tested the hypothesis that the 
cytoplasmic VDR controls breast cancer cell growth.
To explore this hypothesis, we introduced a 
mutant VDR construct which, due to a mutation in the 
Figure 3: VDR knockdown reduces MCF-7 cell growth and induces apoptosis in a ligand-independent manner. (A) In 
ligand-free culture, MCF7-VDR-KD non-clonal cells showed reduced growth by 53% compared to NT cells. Treatment of NT cells with 
1,25D3 reduced cell growth by 44% compared to untreated cells. (B) In ligand free culture, MCF7-VDR-KD uncloned cells showed 6.8-
fold increased apoptosis compared to NT cells, as measured by TUNEL assay. In response to 1,25D3, NT uncloned cells showed 3-fold 
increased apoptosis as compared to untreated cells.(C) Similar to non-clonal cells, VDR-KD#5 showed 41% growth reduction compared 
to MCF7-NT cells. Treatment of MCF7-NT cells with 10–8 M 1,25D3 reduced cell growth by ~50% compared to untreated MCF7-NT cells. 
In contrast, the same treatment has no effect on growth of VDR-KD#5 cells. (D) Similarly, on day 6, VDR-KD#6 had a decreased growth 
by 51%, compared to NT in ligand-free culture. The magnitude of growth inhibition in VDR knockdown clones is comparable to the ligand 
mediated growth inhibition in control cell lines. Treatment of VDR-KD#6 cells with 1,25D3 does not reduce cell growth. (E) Both VDR-KD 
clones exhibited a 3-fold increased rate of apoptosis compared to NT cells in ligand-free culture.  Upon 1,25D3 treatment, NT cell apoptosis 
increased 1.3-fold while VDR knockdown cells showed slightly (but insignificant) increased apoptosis compared to vehicle treated cells.
Results are expressed as the mean ± SEM. For growth assay (n = 6) ***p < 0.001 compared to NT (-D3) using 2-way ANOVA with 
Bonferroni post-test. For TUNEL using 1-way ANOVA with Tukey’s post-test.
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nuclear localization signal in the VDR gene, is unable 
to translocate to the nucleus and thus accumulates in the 
cytoplasm [30]. Importantly, the ligand-binding domain 
of the mutant VDR is not modified and thus is available 
to bind 1,25D3 [31]. As shown in Figure 6A, mRNA 
expression levels of the mutVDR (measured using specific 
primers that detect mutVDR expression only) were similar 
in mutVDR-NT and mutVDR-VDR-KD cells. To confirm 
that expression of the mutant VDR in VDR-KD cells did 
not affect the efficiency of knockdown of endogenous 
VDR, we determined the levels of endogenous VDR 
mRNA using specific primers. As shown in Figure 6B, 
VDR-KD cells expressing the mutant VDR continued to 
show a knockdown of the endogenous VDR, confirming 
that the efficiency of shRNA knockdown of VDR is not 
reduced with concurrent mutVDR expression in these cells. 
VDR Western blots demonstrated ~3-fold increase in VDR 
protein levels in the cytoplasmic fraction of mutVDR-
VDR-KD cells compared to empty vector (EV)-NT 
cells (Figure 6C). Upon treatment with 1,25D3, VDR is 
normally detectable in the nuclear fraction, as is evident 
in EV-transfected cells.  In contrast, mutVDR is much 
less responsive to 1,25D3–induced nuclear translocation 
(Figure 6D). Of note, complete abrogation of nuclear VDR 
Figure 4: VDR knockdown in MCF-7 cells reduces orthotopic tumor growth and also reduces its capability to form 
tumor in the bone environments. (A) Orthotopic tumor growth: Tumors derived from VDR-KD#5 cells grew significantly slower 
than NT cell-derived tumors. (B) Orthotopic tumor weight: At the experiment endpoint (day 50), the tumor mass of mice that received the 
VDR-KD clone was reduced by 72% compared to MCF7-NT. (C) Representative radiographs: Representative images showing osteoblastic 
lesions as indicated by arrows in tibiae injected with MCF7-NT cells 21 weeks p.i. In contrast, no bone changes can be seen in bones 
inoculated with VDR-KD clonal cells. (D) Quantitative histomorphometry: Of the mice implanted with MCF7-NT, 88% developed tumors as 
confirmed by the presence of cancer cells in tibiae. In contrast, only 25% of mice implanted with VDR-KD cells developed tumors. (E) Bone 
histomorphometry: Sclerotic lesion area was significantly greater in MCF7-NT injected bones than in tibiae inoculated with VDR-KD cells.
Results are expressed as the mean ± SEM: Figure A and B (n = 5/group). ***p < 0.001 compared to MCF-N7 NT tumors, using 2-way 
ANOVA with Bonferroni post-test. Figure C to E (n = 8–9/group)., *p < 0.05 , **p < 0.01 compared to NT tumor using 1-way ANOVA 
with Tukey’s post-test.
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translocation was not demonstrated with this mutation, 
which may have resulted in a marginal increase in nuclear 
VDR signals in mutVDR expressing VDR-KD cells.
Cytoplasmic VDR positively controls MCF-7  
breast cancer cell growth in the absence of 
vitamin D
We next compared the growth of EV and mutVDR 
expressing cells in vitro in the presence and absence of 
1,25D3. The growth of the EV-transfected cells (including 
EV-NT and EV-VDR-KD) was comparable to that of non-
transfected cells. In the absence of ligand, the growth 
of mutVDR -transfected NT cells was similar to EV 
transfected NT cells (Figure 7A). As expected, the EV-
VDR-KD clones demonstrated reduced growth in the 
absence of ligand compared to EV-NT cells. However, 
stable expression of the mutVDR in VDR-KD clones 
increased their growth rate to that of EV-NT cells 
(Figure 7A, 7B). These results indicate that the VDR is 
involved in the regulation of MCF-7 cell growth through 
its cytoplasmic accumulation. When mutVDR-VDR-KD 
cells were treated with 1,25D3, they were unresponsive to 
the treatment and there was no suppression of cell growth 
until day 5 (Figure 7C).
Protein tyrosine kinases and protein tyrosine 
phosphatases (PTPs) play a critical role in malignant 
transformation through their tightly regulated activity on 
tyrosine phosphorylation.  Protein tyrosine phosphatase 1 
(PTPH1) has been identified as a specific phosphatase for 
p38γ mitogen-activated protein kinase (MAPK) that shows 
oncogenic activity in cooperation with MAPK through 
direct binding. In human breast cancer cells, PTPH1 
regulates cancer cell growth by its stimulatory effect on 
VDR via its binding to VDR in the cytoplasm [32, 33]. 
To confirm the ligand-independent cytoplasmic function 
of VDR, we measured PTPH1 protein levels in NT and 
VDR-KD cells. In ligand-free conditions, PTPH1 protein 
Figure 5: VDR knockdown in MCF-7 cells decreased osteosclerotic bone formation in bones of nude mice. Bone micro 
CT analysis was performed only for trabecular bone by excluding cortical bone (A) Bone microCT: Representative images showing tumor-
mediated trabecular bone formation in tibiae injected with MCF7-NT cells 21 weeks p.i. In contrast, negligible amounts of trabecular 
bone formation seen in bones inoculated with VDR-KD clonal cells. (B–D) Quantitative analysis of micro-CT scans: Increased trabecular 
bone volume (BV/TV %) was observed in tibiae injected with NT cells compared to contralateral tibiae and VDR-KD inoculated tibiae. 
Trabecular number in the tibiae inoculated with NT cells was significantly higher compared to vehicle control. Tibiae injected with VDR 
knockdown cells showed significantly higher trabecular number compared to vehicle. Similarly, trabecular separation was decreased by 
72% in tibiae with NT cells, compared to vehicle inoculated tibiae. Trabecular separation in VDR-KD inoculated tibia was reduced up to 
13% compared to vehicle-inoculated tibiae.
Results are expressed as the mean ± SEM. *p < 0.05 ,***p < 0.001 compared to NT tumor using 1-way ANOVA  with Tukey’s post-test.
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in cytoplasmic extracts was decreased by 50% in VDR-
KD#5 and by 40% in VDR-KD#6 clones compared to 
NT cells (Figure 7D). When the mutVDR was expressed 
in VDR-KD cells (mutVDR-VDR-KD), PTPH1 protein 
levels were increased by 2-fold in mutVDR-VDR-KD 
clones relative to their respective EV controls (Figure 7E). 
These results support the hypothesis that cytoplasmic 
VDR promotes MCF-7 breast cancer cell growth possibly 
through its action on PTPH1.
DISCUSSION 
By using a stable VDR knockdown approach in vitro 
and in vivo in mouse models, our study demonstrates that 
the cytoplasmic VDR plays an important role in breast 
cancer cell growth. This novel ligand-independent function 
of the VDR to promote cancer cell growth contrasts with 
its canonical ligand-dependent inhibitory nuclear actions 
on cell growth in the presence of vitamin D.
The MCF-7 breast cancer cell line expresses an 
abundance of endogenous VDR, which makes it difficult 
to achieve efficient VDR knockdown. Therefore, we 
performed single cell clonal selection to isolate two clones 
with marked reduction in VDR expression (~ −85%) 
using two controls, PA and NT. The knockdown of VDR 
efficiently blocked VDR-mediated signaling as shown by 
reduced expression of the VDR primary response gene 
CYP24 in the presence of vitamin D.
Consistent with previous reports [23, 26, 34], 
we showed that vitamin D treatment inhibited MCF-7 
cell growth. Based on previous studies that vitamin 
D deficiency promotes breast cancer growth in bone 
Figure 6: Stable expression of nuclear localization mutant VDR (mutVDR) in VDR knockdown clones. (A) After stable 
transfection of mutVDR into VDR knockdown cells the level of mutVDR mRNA in VDR knockdown clones was comparable to MCF7-NT 
cells using mutant VDR specific primers. (B) Expression of mutVDR in VDR-KD#5 and VDR-KD#6 does not change its shRNA knockdown 
effects. (C) Western blot of cytoplasmic fractions and its quantification. After stable transfection of the mutVDR and empty vector (EV) into 
VDR knockdown cells, Western blots demonstrated a ~3-fold increase in mutVDR protein in the cytoplasmic fraction of VDR-KD clones 
compared to EV-transfected NT cells in the absence of vitamin D. (D) Western blot of nuclear fractions and its quantification. Despite 
stable transfection of mutVDR and EV into VDR-KD cells, the mutVDR marginally translocated into the nucleus following treatment with 
10–8M 1,25D3 for 48 hours. In contrast, the intact VDR considerably translocated to the nucleus in EV transfected control cells in response 
to treatment with 1,25D3.
Results are expressed as the mean ± SEM.***p < 0.001 compared to mutVDR-NT using 1-way ANOVA with Tukey’s post-test.
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[26, 27, 35] as well as the known anti-proliferative 
effects of vitamin D on breast cancer cells, we originally 
hypothesized that knockdown of the VDR in breast cancer 
cells would promote tumor cell growth. As expected, 
knockdown of the VDR in MCF-7 cells rendered the 
cells insensitive to vitamin D. However, in contrast to our 
hypothesis, we were surprised to find that VDR knockdown 
alone, in the absence of vitamin D, impaired cell growth. 
These results suggest that the VDR may have the hitherto 
unknown ability to stimulate cell growth independent of 
ligand binding. Experiments measuring the growth of two 
VDR-KD clones and VDR-KD uncloned cells using two 
different assays (MTT and direct cell count) provided 
the same results, indicating that the growth inhibitory 
phenotype of VDR-knockdown cells is not due to off-target 
effects or an artifact in the MCF-7-KD cells.
Our in vivo studies were performed in vitamin 
D-replete mice. Of note, the VDR-KD cells were consistently 
non-responsive to vitamin D treatment in the in vitro 
experiments, which provides evidence that the growth 
suppression seen in VDR-KD cells in vivo is independent 
of vitamin D. The bone microenvironment provides a fertile 
soil for breast cancer cells, and bone is a preferred target 
organ for breast cancer metastasis [7, 36, 37]. MCF-7 cells 
have previously been reported to form mixed osteolytic 
and osteoblastic bone lesions in which both osteoclasts 
and osteoblasts act to support tumor growth [36, 38, 39]. 
Our in vivo experiments indicate that ablation of the VDR 
in MCF-7 cells strongly reduces tumor formation within 
the bone environment, since about 87% of the mice failed 
to develop histologically visible tumors or tumor-related 
changes in the bone. In contrast, visible osteoblastic tumors 
were seen in 8 out of 9 tibiae inoculated with NT cells. The 
tumors seen in the two mice that did develop visible lesions 
following injection of VDR-KD clones were comparable in 
size and structure to those formed in mice injected with NT. 
Figure 7: Expression of mutVDR into the VDR knockdown cells restores their growth. (A–B) Similar to VDR-KD cells, 
in ligand-free culture the EV-VDR-KD clones were slow in growth compared to EV-NT. Stable expression of the mutVDR in VDR-KD 
clones rescued the growth phenotype of VDR knockdown cells. mutVDR expression in both knockdown clones resulted in similar increases 
in growth rate. This was comparable to the growth rate of EV-NT cells. (C) When mutVDR -VDR-KD clones were treated with 1,25D3, 
they were unresponsive to treatment, thus cell growth remained the same until day 5. A slight reduction in growth was observed on day 6. 
(D) Western blots of the cytoplasmic fraction showed that compared to NT, PTPH1 protein levels were decreased by 50% in VDR-KD#5 
and 40% in VDR-KD#6 (E) After mutVDR expression, PTPH1 protein was increased by 2 fold in cytoplasm of mutVDR -VDR-KD clones 
compared to their respective EV controls.
Results are expressed as the mean ± SEM (n = 6). ***p < 0.001 compared to EV-NT (−D3), mutVDR-VDR-KD#5 (-D3), mutVDR-VDR-
KD#6 (-D3), mutVDR-NT(-D3), mutVDR-VDR-KD#5 (+D3), mutVDR-VDR-KD#6 (+D3) using 2-way ANOVA with Bonferroni post-test.
Oncotarget26696www.impactjournals.com/oncotarget
These tibiae also showed a radiographic phenotype equivalent 
to that seen in the MCF7-NT group. One reason for the 
apparent impairment in tumor development with VDR-KD 
cells could be that the time required for inoculated cells 
to commence rapid proliferation and form tumours in 
VDR-KD cells is longer than that for the control cells. 
Alternatively, it could represent a reduced ability of 
VDR-KD cells to survive inoculation and introduction to a 
bone environment. 
As the ligand-independent function of the VDR has 
not been widely studied, little information is available on 
the ligand-independent properties of the VDR. In skin 
cells, the unliganded VDR is required for keratinocyte 
stem cell function through interaction with the Wnt-β-
catenin signaling pathway [40, 41]. In breast cancer, a 
single in vitro study has identified that PTPH1 positively 
regulates breast cancer growth by its stimulatory effect 
on VDR protein expression [32]. VDR localization and 
its specific effects are an emerging field of research and 
the findings we reported in this study contribute to our 
understanding of the phenotypic effects of cytoplasmic 
VDR on cancer cells.  Furthermore, it has been reported 
that in the absence of its ligand, the VDR is distributed 
between the cytoplasm and the nucleus [30, 42]. VDR 
localization and its dependence on ligand binding 
are not absolute, though, as shown by us and others 
[24, 26, 27, 29], ligand binding is associated with 
enhanced shuttling of the VDR from the cytoplasm to the 
nucleus. However, recent evidence suggests that shuttling 
of the unliganded VDR to the nucleus produces basal 
transcriptional activity via binding to co-repressors or co-
activators [43–47]. Global chromatin immunoprecipitation 
(ChIP) analyses have also indicated that a significant 
number of DNA-binding sites are occupied by the VDR 
in the absence of its cognate ligand [48].  However, the 
role of cytoplasmic VDR in the absence of ligand is not 
well studied. Our VDR knockdown results suggest a 
different role than expected and have led us to propose 
that the cytoplasmic VDR could be a factor contributing 
to the regulation of breast cancer cell proliferation. To 
investigate this further, we successfully created conditions 
that induced accumulation of VDR in the cell cytoplasm 
using stable expression of a mutant form of VDR. 
Stable expression of mutVDR increased the growth 
of VDR knockdown cells to that of unmodified NT cells. 
This experiment demonstrated that in absence of its 
ligand, the cytoplasmic VDR promotes cell growth, a 
function that is in stark contrast to the inhibitory effects of 
the liganded VDR following nuclear translocation. Using 
Western immunoblotting, we have detected the presence 
of PTPH1 protein in cytosolic extracts of NT cells and its 
absence in VDR-KD cells. When the VDR was artificially 
accumulated in the cytoplasm of MCF7-KD cells using 
the mutant VDR, PTPH1 also increased corresponding 
to increased cytoplasmic VDR expression. These results 
support the concept that the cytoplasmic VDR controls 
MCF-7 cell growth. Altered PTPH1 levels with respect to 
VDR localization may be the responsible factor mediating 
the actions of unliganded cytoplasmic VDR but the 
detailed molecular interactions between their cytoplasmic 
association and cellular response remain to be elucidated.
Vitamin D deficiency is common in women with 
breast cancer at advanced disease stages [8–10]. However, 
the relationship between vitamin D status and clinical 
outcomes remain controversial. Numerous studies have 
linked low serum concentrations of 25-hydroxyvitamin 
D with increased cancer incidence and more aggressive 
tumor behavior, including increased bone metastasis 
and decreased survival [8, 10, 49]. However, most of 
these reports are epidemiological or clinical association 
studies, which cannot establish cause and effect, nor do 
they provide plausible mechanistic concepts. It is therefore 
not surprising that other reports are inconsistent with the 
relationship suggested by clinical and epidemiological 
studies [50, 51]. As the VDR is the central modulator of 
the autocrine/paracrine response to vitamin D, some of 
the inconsistencies in the above quoted clinical studies 
regarding the correlation between vitamin D status and 
breast cancer might be due to differences in VDR status 
[18, 52]. Our mostly observational study indicates that apart 
from vitamin D levels, VDR status and its compartmental 
distribution may contribute to regulating breast cancer cell 
growth. The use of a single model cell line is a limitation 
of this study and it is currently unknown if cytoplasmic 
VDR accumulation causes similar effects in other cancer 
cell lines. Detailed investigation into mechanisms behind 
ligand-independent cytoplasmic activity of VDR under 
conditions of vitamin D deficiency would have clinical 
applicability in deciding the treatment strategies in patients 
with breast cancer. Measuring nuclear and cytoplasmic 
VDR expression in human tumors at different stages of 
progression and correlating these results with the patient’s 
vitamin D status would help to clarify whether cytoplasmic 
accumulation of VDR might be relevant in regulating 
tumor growth in patients. A prospective clinical trial would 
be required to determine such a relationship, and this could 
help clarify the clinical discrepancies reported with regard 
to vitamin D and tumor outcomes [50].
In conclusion, this study demonstrates that 
cytoplasmic VDR can control MCF-7 breast cancer cell 
growth independent of vitamin D. Further investigations 
into the underlying mechanisms may deepen our 
understanding of the role of the VDR in cancer cell 
behavior and thus may open new therapeutic approaches 
for patients with metastatic breast cancer.
MATERIALS AND METHODS
Cell line
The human breast cancer cell line MCF-7 was 
selected for these studies as it expresses the VDR at 
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relatively high levels and is responsive to 1,25D3 [24]. 
MCF-7 cells were obtained from Garvan’s Cancer Group 
which is now known as Kinghorn Cancer Centre. We 
have authenticated these cells as human by probing RNA 
with human specific probes for housekeeping genes and 
confirmed their expected phenotype of high estrogen 
dependence and high sensitivity to growth inhibition 
by 1,25D3 treatment, and by their induction of mixed 
osteogenic/osteoblastic lesions when implanted in 
tibiae. MCF-7 cells were maintained in RPMI medium 
supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin solution and 200 µg/mL insulin 
(Sigma, MO, USA) in a 37°C humidified atmosphere with 
5% CO2. All the experiments used cells of ≤ 5 passages. 
Cells were routinely tested for the absence of mycoplasma 
contamination using mycoplasma GoTaq M5005 detection 
kit (Promega Corporation, WI, USA). 
Stable shRNA knockdown and preparation of 
stable clones
Parental MCF-7 cells (PA) were transduced with 
a lentivirus encoding shRNA against the VDR (shVDR, 
TRCN000019506, MISSION shRNA, Sigma) (VDR-KD). 
Cells transduced with a non-target shRNA control vector 
(shNT, SHC002V, Sigma) were used as controls (NT). 
Two VDR-shRNA constructs were tested and the one with 
best knockdown efficiency was used for VDR knockdown 
and subsequent clonal selection. VDR-KD and NT cells 
were selected from heterogeneous pools using 2 µg/mL 
puromycin (Sigma). Clonal selection for both NT and 
VDR-KD was carried out using limiting dilution in 
the presence of puromycin in a 96-well plate format. 
Using this method, 30 NT and 27 VDR-KD clones were 
prepared, maintained and screened at mRNA and protein 
levels to identify clones with high VDR knockdown 
efficiency. From these, one NT and two VDR-KD (#5 and 
#6) clones were selected for further in vitro and in vivo 
experiments. The selection of two VDR knockdown 
clones reduced the possibility of clonal as well as off-
target effects. Throughout this study both the knockdown 
clones showed a similar phenotype. Initially, we used both 
PA and NT as controls, however as they each showed a 
similar phenotype we continued all experiments using NT 
as a control since it had been generated in parallel with the 
VDR-KD clones.
Nuclear localization signal (NLS) mutant VDR 
(mutVDR) overexpression 
The NT and VDR-KD MCF-7 cells were transfected 
with a mutated form of the VDR (mutVDR), which due 
to a mutation in the nuclear localization (NLS) signal is 
unable to translocate to the nucleus (kindly provided by 
Prof Chen, Medical College of Wisconsin, USA). The 
mutVDR was originally generated by Prufer et al. through 
point mutations of the K53Q, R54G and K55E basic amino 
acids in the NLS-I of VDR and cloned into a V5-tagged 
pcDNA3.1 vector [30]. A pcDNA3.1 empty vector (EV) 
was used as a control. MCF-7 cells (NT and VDR-KD 
clones) were plated in 6-well plates at 3 × 105 cells/well 
and transfected using LipofectamineTM (10 μg DNA per 
well) [53]. From the next day forward, cells were selected 
using the G418 antibiotic (1 mg/mL) for 3–5 days. After 
selection, mutVDR -expression was confirmed using real 
time-PCR and western blotting. For the purpose of this 
study, the cells resulting from this transfection will be 
referred to as mutVDR -NT, mutVDR -VDR-KD, EV-NT 
and EV-VDR-KD. 
Quantitative RT-PCR
For gene expression studies, total RNA was isolated 
using GenElute RNA miniprep kits (Sigma) or Nucleospin 
RNA II kits (Macherey-Nagel GmbH & Co. KG) from 
the cells treated with 10–8M 1,25D3 (Biomole, ENZO 
life sciences, NY, USA) or its vehicle (ethanol) for the 
times indicated under serum-free conditions (0.1% BSA 
containing RPMI media supplemented with 1% penicillin 
streptomycin solution and 200µg/mL insulin). Total RNA 
(500 ng/sample) was reverse-transcribed using Superscript 
III (Life Technologies, CA, USA) after oligo(dT) primers 
(Promega Corp, WI, USA). Real-time PCR was performed 
using Hot start-IT SYBR green Q-PCR master mix 
(Affymetrix, Inc. USB products, CA, USA) with Bio-
Rad CFX96 Thermal Cycler (Bio-Rad, CA, USA), or 
alternately, using iQSYBR-Green SuperMix (Bio-Rad) with 
Bio-Rad thermal cycler (Bio-Rad). Primers were optimized 
for RT-PCR target gene expression, which was normalized 
against the housekeeping gene, GAPDH. mRNA levels for 
gene expression of human GADPH, VDR, CYP24A1, and 
mutant VDR were assessed by real-time RT-PCR using 
species-specific primers. Primer sequences were: hGAPDH 
(Forward 5′-TATGACAACGAATTTGGCTACAG-3′; 
Reverse 5′-GATGGTACATGACAAGGTGC-3′); hVDR 
(Forward 5′-ACCTGGACAACAAGAGCGA-3′; Reverse 
5′-CTCCTTCCTTCTCCTTCTGATG-3′); hCYP24A1 
(Forward 5′-GCATCTTCCATTT GGCGT-3′; Reverse 
5′-AATACCACCATCTGAGGCGT-3′); hmutantVDR 
(Forward 5′-CCACCTGCTCTATGCCAAG-3′; Reverse 
5′-GAAAGGACAGTGGGAGTG-3′).
Cell fractionation and Western blot analysis
NT and VDR-KD cells or their mutVDR or EV 
transfected counterparts were treated with 10–8M 1,25D3 
or vehicle (0.1% ethanol) in RPMI medium supplemented 
with 2% charcoal stripped, heat-inactivated FBS and 
200 µg/mL insulin. In our hands, untreated FBS contains 
1,25D3 at a concentration of 360pM when measured 
by specific RIA (Diasorin, USA). In contrast, 1,25D3 
concentrations were undetectable in media supplemented 
Oncotarget26698www.impactjournals.com/oncotarget
with 2% charcoal stripped heat-inactivated FBS. 
Moreover, when MCF-7 cells were cultured in serum-
free media or in media supplemented with 2% charcoal 
stripped heat-inactivated FBS, induction of CYP24 
expression was not observed. We therefore considered 
culture media supplemented with 2% charcoal stripped 
heat-inactivated serum, 1% penicillin streptomycin 
solution and 200 µg/mL insulin to be free of 1,25D3 and 
refer to it as ligand-free media.
Media was changed every 24 hours. After 48 hours, 
whole cell lysates were prepared using RIPA buffer 
supplemented with protease inhibitor cocktail (Roche 
Pharmaceutical Co., Germany). Total protein concentration 
was determined using a Bradford assay (BioRad, CA, 
USA). Samples were loaded on 8% polyacrylamide gels 
and electrophoresis was performed using a Mini Trans-Blot 
cell (BioRad). Proteins were transferred onto a Hybond™-P 
membrane (GE Healthcare, WI, USA) using a Mini-
PROTEAN Cell transfer system (Bio-Rad). Alternatively, 
cell fractions were prepared using NE-PER Nuclear and 
Cytoplasmic Extraction reagent kits (Thermo Scientific, IL, 
USA) followed by protein estimation using a BCA protein 
assay (Thermo Scientific, IL, USA). Samples were loaded on 
Bolt, 4–12% mini gels, separated and transferred using the Bolt 
electrophoresis system and reagents (Invitrogen, CA, USA).
Membranes were blocked in TBS-T-5% milk for 
1 h, incubated overnight with the primary antibody and for 
1 h with the secondary antibody. Antibody detection was 
performed using Immobilon™ Western Chemiluminescent 
HRP Substrate (Millipore, MA, USA) according to the 
manufacturer’s directions, and signal was detected either 
on Image Quant LAS4000 (GE healthcare) or BioRad 
Image gel system (BioRad). Primary antibodies included 
anti-VDR (Clone 9A7γ.E10.E4, Neo Markers, CA, USA), 
anti-PTPH1 (Santa Cruz Biotechnology, CA, USA), anti-
α-tubulin (Sigma), anti-Lamin-A (AbCam, MA, USA). 
Secondary antibodies included anti-Rat (R&D system, MN, 
USA), anti-goat (Santa Cruz Biotechnology) Anti-mouse 
IgG, and anti-rabbit IgG (Sigma). A Western blot of VDR 
from cell extracts showed several bands, consistent with 
previously published studies using an anti-VDR antibody 
clone similar to that employed in our study [54–56]. 
Cell growth assay
Proliferation of NT and VDR-KD cells, or their 
mutVDR or EV transfected counterparts, was assessed 
either by MTT assay or using direct cell counting. Cells 
were seeded in 2% charcoal stripped FBS (see above) 
containing RPMI media and were treated with either 10–8M 
1,25D3 or vehicle (0.1% ethanol) and media were replaced 
every 24hrs. For the MTT assay, MTT reagent (5mg/mL) 
(Calbiochem, CA, USA) was added to each well. After 
incubation for 4hrs at 37°C, cells were lysed using a PBS 
solution with SDS (10%) and HCl (0.01N), and the plate 
was incubated at 37°C for an additional 16 hrs. Absorbance 
was measured at 570 nm using an OPTIMA (BMG 
lab tech, VI, USA) plate reader. Alternatively, treated 
cells were counted daily by trypan blue exclusion after 
trypsinizing until they reached 100% confluence on day 
four. Experiments were repeated 3 times in independent 
settings to ensure validity of the results.
Cell apoptosis assay
NT and VDR-KD cells were cultured in medium 
containing 2% charcoal stripped FBS and treated with 
either 0.1% ethanol or 10−8M 1,25D3 for 6 days. Culture 
media was replaced every 24 hrs. Apoptosis was measured 
by TUNEL assay using the in situ cell death detection kit, 
POD (Roche Pharmaceutical Co., Germany). TUNEL-
positive and total cells were counted in 3–5 random fields/
well at 400× magnification. 
Animal experiments
Four-week-old female athymic nude mice with 
body weight of 18–20 grams were purchased from Harlan 
(Indianapolis, IN, USA). Animal experiments were 
performed at Indiana University School of Medicine, IN, 
USA following approval by Indiana University Institutional 
Animal Care and Use Committee. 
Mammary fat pad tumor model
Twenty 4-week-old female nude mice were 
randomized into 2 groups (n = 5/group). Both groups of mice 
were implanted with sustained release pellets containing 
0.72 mg of 17ß estradiol (E2) (Innovative Research of 
America, FL, USA) subcutaneously on the lateral side of 
the neck, followed by subcutaneous implantation of NT 
and VDR-KD#5 cells [54]. Cells were suspended in cold 
Matrigel/PBS (1:1) at a concentration of 2 × 107 cells/mL. 
100 µL of the suspension (2 × 106 cells) was implanted into 
the fourth mammary fat pad using a 27-gauge needle [26]. 
Starting from day 14, tumor dimensions were measured 
every three days using a precision calliper and tumor volume 
was calculated using the formula (length × width2)/2. Tumor 
weight was measured at the termination of the study (day 50).
Intratibial xenograft model
Fifty-two 4-week-old female nude mice were 
divided into three groups (n = 13/group): NT, VDR-KD#5, 
VDR-KD#6. Under general anaesthesia with ketamine/
xylazine 75/10 mg/kg i.p., 2 × 105 cells in 20 µL of cell 
suspension (NT and VDR-KD clonal lines) were slowly 
injected through the knee joint into the tibial plateau of the 
left tibia using a Hamilton syringe [53, 57]. Contralateral 
tibiae were injected similarly with vehicle alone (PBS). As 
MCF-7 cells produce predominantly osteoblastic lesions, 
tumor growth was monitored every three weeks by digital 
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radiography using a Kubtec Xpert80 (Kubtec digital 
X-ray, Milford, CT, USA). 
Micro-computed tomography (Micro-CT)
MicroCT analyses were performed using a VivaCT 
40 scanner (Scanco Medical, Bassersdorf, Switzerland). 
Mice were positioned on the microCT bed under 
continuous isoflurane anesthesia and oxygen. After 
defining the region of interest, the proximal tibia was 
scanned at high resolution with 10 µm voxel size and 
200 ms integration time. For the trabecular bone analysis, 
trabecular contours were drawn beginning 300 μm below 
the growth plate and extending for 7.6 mm -9.5 mm. 
The same number of slices were analysed in both legs. 
Parameters measured included: trabecular bone volume 
per total volume (BV/TV, %), trabecular number (Tb.N, 
mm−1) and trabecular separation (Tb.Sp, mm).  All values 
were compared with the contralateral vehicle injected tibia.
Bone histology and histomorphometry
Tibiae collected from 6–8 mice/group were used 
for paraffin embedding and 5–6 mice/group for plastic 
embedding. Tibiae from mice inoculated with tumor/
sham intratibially were collected after euthanasia 
and fixed in 10% neutral buffered formalin for 48 h, 
followed by decalcification in 10% EDTA for 3 weeks. 
After embedding in paraffin, longitudinal mid-sagittal 
sections of 3.5 µm in thickness were cut and stained with 
haematoxylin & eosin (MUTVDR&E). Plastic embedded 
specimens were cut using an automated microtome 
(Microm HM 360, Thermo Scientific). Longitudinal mid-
sagittal sections of 4.5µm in thickness were placed on 
slides coated with Haupt’s solution and incubated at 37ºC 
overnight. Sections were then stained with Von Kossa 
MacNeal’s Tetrachrome to distinguish newly formed 
osteoid from mineralized bone. Both paraffin and plastic 
embedded sections were visualized, captured and analysed 
at 12.5× to 400× magnification using an OsteoMeasure 
Image Analysis software v.13.2 System (Osteometrics, 
Atlanta, GA, USA) to determine total tissue area, tumor 
area and new woven bone formation in sclerotic lesions.
Statistical analysis
Data were analysed using GraphPad Prism version 
5 (GraphPad, La Jolla, CA, USA). For simple comparison 
of two means, Student’s t test was performed. One-way 
ANOVA followed by Tukey’s post-test was used when 
comparing three groups or more. A 2-way ANOVA 
followed by Bonferroni post-test was used to compare 
groups affected by 2 variables. In vitro experiments 
were performed three times. Results shown are from 
a representative experiment. Data are presented as 
mean ± SEM. A p-value < 0.05 was considered significant.
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